[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-349567-105":3,"doc-detail-349567-en":81,"detail-sidebar-cat-0-en-105":116},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","immune-checkpoint-inhibitor-based-combinatory-and-alternative-strategies-for-immune-treatment-of-lung-cancers-review","Immune checkpoint inhibitor-based combinatory and alternative strategies for immune treatment of lung cancers - Review","","Immune checkpoint inhibitors (ICIs), especially antibodies targeting PD-1/PD-L1 and CTLA-4, have changed lung cancer treatment, yet only a subset of patients benefits durably because of primary and acquired resistance. This review frames a lung cancer–centered scope and summarizes established and emerging ICI-based regimens, resistance mechanisms relevant to both NSCLC and SCLC, and biomarker integration for patient selection and monitoring. It also outlines future directions to improve efficacy and safety via combinatory and alternative immunotherapeutic strategies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/immune-checkpoint-inhibitor-based-combinatory-and-alternative-strategies-for-immune-treatment-of-lung-cancers-review/349567/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/immune-checkpoint-inhibitor-based-combinatory-and-alternative-strategies-for-immune-treatment-of-lung-cancers-review/349567.png","ImageObject",300,407,{"name":42,"@type":43},"mieayamfan","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",17,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why do only some lung cancer patients benefit durably from immune checkpoint inhibitors?","Question",{"text":63,"@type":64},"Durable benefit is limited by primary and acquired resistance driven by tumor-intrinsic factors, tumor microenvironment constraints, and evolving biomarkers.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which immune checkpoint targets are highlighted in this review?",{"text":68,"@type":64},"The review focuses on ICIs targeting PD-1/PD-L1 and CTLA-4, and also discusses additional inhibitory and stimulatory receptors such as LAG-3, TIM-3, and TIGIT.",{"name":70,"@type":61,"acceptedAnswer":71},"What topics does the review cover regarding treatment strategies?",{"text":72,"@type":64},"It summarizes ICI-based regimens in lung cancer, resistance mechanisms for NSCLC and SCLC, biomarker integration for selection and monitoring, and future directions for optimizing efficacy and safety through combinatory and alternative immunotherapies.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},349567,1790471917,{"code":4,"msg":82,"data":83},"success",{"doc_id":79,"user_id":84,"nickname":42,"user_avatar":85,"doc_module":4,"category_id":86,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":87,"file_id":88,"file_url":89,"file_type":90,"file_size":91,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":92,"language":93,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":94,"faqs":95,"seo_title":96,"seo_description":12,"update_tm":97,"read_time":98,"preview_page_count":33,"preview_urls":99},962090893677,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2",8,"TYPE Review  \nPUBLISHED 10 August 2026  \nDOI 10.3389/fimmu.2026.1878931  \nOPEN ACCESS  \nEDITED BY  \nMassimo Fantini,  \nPrecision Biologics, Inc., United States  \nREVIEWED BY  \nKatia Mangano, University of Catania, Italy Manal Kanaan,  \nMiddle Technical University, Iraq  \n*CORRESPONDENCE  \nCheorl-Ho Kim  \n [chkimbio@skku.edu](chkimbio@skku.edu)[ ](chkimbio@skku.edu)Yu-Chan Chang  \n[yuchanchang@nycu.edu.tw](yuchanchang@nycu.edu.tw)[ ](yuchanchang@nycu.edu.tw)RECEIVED 12 May 2026 REVISED 01 July 2026 ACCEPTED 08 July 2026 PUBLISHED 10 August 2026  \nCITATION  \nPark J-Y, Kwak C-H, Chang Y-C and Kim C-H (2026) Immune checkpoint inhibitor-based combinatory and alternative strategies for immune treatment of lung cancers.  \nFront. Immunol. 17:1878931 .  \ndoi: 10.3389/fimmu.2026.1878931  \nCOPYRIGHT  \n© 2026 Park, Kwak, Chang and Kim. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nImmune checkpoint inhibitorbased combinatory and alternative strategies for immune treatment of lung cancers  \nJun-Young Park 1,2, Choong-Hwan Kwak 1,3, Yu-Chan Chang 4* and Cheorl-Ho Kim 1*  \n1 Molecular and Cellular Glycobiology Unit, Department of Biological Sciences, SungKyunKwan University, Suwon, Gyunggi-Do, Republic of Korea, 2 Environmental Diseases Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea, 3 Department of Brewing, Dong-Eui Institute of Technology, Busan, Republic of Korea, 4 Department of Biomedicine Imaging and Radiological Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan  \nImmune checkpoint inhibitors (ICIs), particularly antibodies targeting PD-1/PD-L1 and CTLA-4, have reshaped the treatment landscape of lung cancers, most notably non-small cell lung cancer (NSCLC) . Nevertheless, only a subset of patients achieve durable beneﬁt due to primary and acquired resistance that arises from tumor-intrinsic factors (e. g., oncogenic drivers and adaptive signaling), tumor-extrinsic determinants in the tumor microenvironment (TME) (e. g., impaired T-cell inﬁltration and immunosuppressive myeloid populations), and the dynamic evolution of biomarkers. Accordingly, current clinical and translational efforts in lung cancer focus on rational combination strategies—ICIs with chemotherapy, radiotherapy, and targeted agents (including RTK-and KRAS-pathway inhibitors)—as well as alternative approaches that modulate antigen presentation, myeloid regulation, and cancer stemness. In this review, we deﬁne a lung cancer– centered scope and summarize (i) established and emerging ICI-based regimensin lung cancer, (ii) mechanisms of resistance relevant to NSCLC and SCLC, (iii) biomarker integration for patient selection and monitoring, and (iv) future directions to optimize efﬁcacy and safety through combinatory and alternative immunotherapeutic strategies.  \nKEYWORDS  \nanti-PD-l/PD-LI therapy, cancer cells, ICI, KRAS, therapy-resistant tumors  \n1 Introduction  \nThe immune system maintains homeostasis by surveying pathogenic invaders and transformed cells through continuous communication between host cells and their environments. Immune checkpoints are physiological regulators that limit excessive Tcell activation and maintain self-tolerance. In cancer, tumors frequently exploit these pathways—most prominently the PD-1/PD-L1 axis and CTLA-4—to suppress anti-tumor immunity within the tumor microenvironment (TME) (1) . In cancer, immune evasion is promoted by genetic instability and tumor evolution, which generate heterogeneous subclones and neoantigen landscapes (2). Importantly for lung cancer, smokin","cbCaivcG6ceBPGP3","https://ap.wps.com/l/cbCaivcG6ceBPGP3","pdf",2301229,19,"English","# Introduction\n## Immune checkpoints in cancer and lung cancer context\n# Key clinical ICI agents and combination rationale\n## Beyond PD-1/PD-L1 and CTLA-4: additional receptors\n## Mechanistic and biomarker-driven treatment considerations","[{\"question\":\"Why do only some lung cancer patients benefit durably from immune checkpoint inhibitors?\",\"answer\":\"Durable benefit is limited by primary and acquired resistance driven by tumor-intrinsic factors, tumor microenvironment constraints, and evolving biomarkers.\"},{\"question\":\"Which immune checkpoint targets are highlighted in this review?\",\"answer\":\"The review focuses on ICIs targeting PD-1/PD-L1 and CTLA-4, and also discusses additional inhibitory and stimulatory receptors such as LAG-3, TIM-3, and TIGIT.\"},{\"question\":\"What topics does the review cover regarding treatment strategies?\",\"answer\":\"It summarizes ICI-based regimens in lung cancer, resistance mechanisms for NSCLC and SCLC, biomarker integration for selection and monitoring, and future directions for optimizing efficacy and safety through combinatory and alternative immunotherapies.\"}]","Immune checkpoint inhibitor-based combinatory and alternative strategies for immune treatment of lung cancers - Review | PDF",1790084335,48,[100,104,108,112],{"page_no":22,"url":101,"width":102,"height":103},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/559ce852c1ff02cf6284aff1768811bc.webp",983,1389,{"page_no":26,"url":105,"width":106,"height":107},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8a25bbbb86c751511c4997a94a934c05.webp",982,1388,{"page_no":30,"url":109,"width":110,"height":111},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/96f1bdcde2e5c2f69a6208b2e78fa647.webp",981,1386,{"page_no":33,"url":113,"width":114,"height":115},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6ee003425eaf4ad3c72553831efe949c.webp",980,1385,{"code":4,"msg":82,"data":117},[118,122,126,130,135,140,145,148,153,156,160],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":119,"show_sort_weight":120,"slug":121},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":123,"show_sort_weight":124,"slug":125},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":127,"show_sort_weight":128,"slug":129},"Exam",70,"exam",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":133,"slug":134},5,"Comic",60,"comic",{"id":136,"doc_module":4,"doc_module_name":25,"category_name":137,"show_sort_weight":138,"slug":139},6,"Technology",50,"technology",{"id":141,"doc_module":4,"doc_module_name":25,"category_name":142,"show_sort_weight":143,"slug":144},7,"Healthcare",40,"healthcare",{"id":86,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":146,"slug":147},30,"research-report",{"id":149,"doc_module":4,"doc_module_name":25,"category_name":150,"show_sort_weight":151,"slug":152},9,"Religion & Spirituality",20,"religion-spirituality",{"id":151,"doc_module":4,"doc_module_name":25,"category_name":154,"show_sort_weight":151,"slug":155},"World Cup","world-cup",{"id":157,"doc_module":4,"doc_module_name":25,"category_name":158,"show_sort_weight":157,"slug":159},10,"Lifestyle","lifestyle",{"id":92,"doc_module":4,"doc_module_name":25,"category_name":161,"show_sort_weight":131,"slug":162},"General","general"]